Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 17/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588228 | 0.88 | FAAH (1.00) | FAAHLMNAKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL3603903 | 0.87 | FAAH (0.98) | FAAHLMNAKDM4EMAPT | |
| SCHEMBL3595624 | 0.85 | FAAH (1.00) | FAAHKDM4EMAPTCA12CA2 | |
| SCHEMBL3602752 | 0.83 | FAAH (1.00) | FAAHLMNAKDM4EMAPT | |
| SCHEMBL3599605 | 0.79 | FAAH (1.00) | FAAHKDM4EMAPTCA12CA2 | |
| SCHEMBL3602903 | 0.78 | FAAH (1.00) | FAAHKDM4EMAPTCA12CA2 | |
| SCHEMBL15217834 | 0.77 | FAAH (0.73) | FAAHKDM4EMAPT | |
| SCHEMBL3590774 | 0.77 | FAAH (1.00) | FAAH | |
| SCHEMBL3602524 | 0.77 | FAAH (1.00) | FAAHKDM4EMAPT | |
| SCHEMBL4306572 | 0.77 | FAAH (0.75) | FAAHKDM4EMAPTCA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | UNITED STATES OF AMERICA (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | FAAH, FAAH2, PNLIP | FAAH 1/4885LMNA 3932/4885KDM4E 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.